Application
A. Western blot analysis on (left) K562 and (right) Daudi cell lysates using anti-CKR7/CCR7 (N-term) RabMAb (Cat. #AJ1144b), dilution 1:5,000.Application
B. Immunohistochemical analysis of paraffin-embedded human spleen using anti-CKR7/CCR7 (N-term) RabMAb (Cat. #AJ1144b).Application
C. Immunofluorescent staining of HeLa cells using anti-CKR7/CCR7 (N-term) RabMAb (Cat. #AJ1144b).| Product Name | CCR7/CKR7 Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Clonality | Monoclonal |
|---|---|
| Clone Number | Y59 |
| Host Species | Rabbit |
| Tested Applications | WBIHCIF |
| WB:1:10000 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | CMKBR7, EBI1, EVI1 |
|---|---|
| Alternative Names | CCR7 CMKBR7 EBI1 EVI1 C-C chemokine receptor type 7 BLR2 CDw197 |
| Molecular Weight(MW) | 42874 Da |
| Function | Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions |
| Tissue Specificity | Expressed in various lymphoid tissues and activated B- and T-lymphocytes, strongly up-regulated in B-cells infected with Epstein-Barr virus and T-cells infected with herpesvirus 6 or 7 |
| Cellular Localization | Cell membrane; Multi-pass membrane protein. |
| Entrez Gene | 1236 |
|---|
Application
A. Western blot analysis on (left) K562 and (right) Daudi cell lysates using anti-CKR7/CCR7 (N-term) RabMAb (Cat. #AJ1144b), dilution 1:5,000.
Application
B. Immunohistochemical analysis of paraffin-embedded human spleen using anti-CKR7/CCR7 (N-term) RabMAb (Cat. #AJ1144b).
Application
C. Immunofluorescent staining of HeLa cells using anti-CKR7/CCR7 (N-term) RabMAb (Cat. #AJ1144b).| Application Notes | WB:1:10000 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
